Regenxbio's muscle disorder therapy meets main goal in late-stage study
14/05/2026 12:03
May 14 (Reuters) - Regenxbio RGNX.O said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed) ((Padmanabhan.Ananthan@thomsonreuters.com;))